Beyond HLA: An adaptive nanopore sequencing assay for simultaneous HLA and blood group profiling in transplantation

As a field, we have dramatically reduced early post-transplant immune injury using molecular diagnostics and structural biology. Here, we demonstrate proof-of-concept of a personalized transplant risk assessment, which can be adapted to profile additional genes or genomic regions within minutes and yields multi-genic typing data at a 4-day turnaround. This approach represents the next step in refining precision medicine, improving patient outcomes, reducing healthcare costs, and enhancing life quality for transplant recipients.